| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $1,156,546 | 2 | 8 |
Sells | $10,730,318 | 24 | 92 |
| Davis Todd C | Chief Executive Officer | 1 | $1M | 0 | $0 | $1M |
| Espinoza Octavio | Chief Financial Officer | 1 | $156,090 | 3 | $3.79M | $-3.63M |
| Sabba Stephen L | director | 0 | $0 | 2 | $617,724 | $-617,724 |
| Gray Nancy Ryan | director | 0 | $0 | 1 | $619,432 | $-619,432 |
| LAMATTINA JOHN L | director | 0 | $0 | 2 | $851,728 | $-851,728 |
| KOZARICH JOHN W | director | 0 | $0 | 10 | $886,682 | $-886,682 |
| Aryeh Jason | director | 0 | $0 | 1 | $1.71M | $-1.71M |
| Reardon Andrew | CLO & Secretary | 0 | $0 | 5 | $2.26M | $-2.26M |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Over the last 12 months, insiders at Ligand Pharmaceuticals Incorporated have bought $1.16M and sold $10.73M worth of Ligand Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Ligand Pharmaceuticals Incorporated have bought $461,116 and sold $6.09M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Davis Todd C (Chief Executive Officer) — $1M. Espinoza Octavio (Chief Financial Officer) — $156,090.
The last purchase of 9,510 shares for transaction amount of $1M was made by Davis Todd C (Chief Executive Officer) on 2025‑05‑09.
| 2026-04-01 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $202.23 | $94,440 | +2.44% | |
| 2026-04-01 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.0253% | $201.24 | $1.01M | +2.44% | |
| 2026-03-23 | Sale | Sabba Stephen L | director | 1,000 0.0052% | $207.87 | $207,873 | -1.36% | |
| 2026-03-11 | Sale | Espinoza Octavio | Chief Financial Officer | 3,057 0.0156% | $225.00 | $687,825 | -6.89% | |
| 2026-03-06 | Sale | LAMATTINA JOHN L | director | 2,161 0.0109% | $200.76 | $433,842 | +2.39% | |
| 2026-03-04 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.0251% | $206.35 | $1.03M | -1.28% | |
| 2026-03-04 | Sale | Espinoza Octavio | Chief Financial Officer | 13,423 0.0672% | $205.83 | $2.76M | -1.28% | |
| 2026-03-03 | Sale | Sabba Stephen L | director | 2,034 0.0103% | $201.50 | $409,851 | +1.11% | |
| 2026-03-02 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $200.50 | $93,632 | +1.84% | |
| 2026-02-02 | Sale | KOZARICH JOHN W | director | 467 0.0023% | $195.91 | $91,490 | +2.43% | |
| 2026-01-02 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $189.58 | $88,532 | +5.21% | |
| 2025-12-12 | Sale | Espinoza Octavio | Chief Financial Officer | 1,804 0.0091% | $188.31 | $339,711 | +4.63% | |
| 2025-12-01 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $195.84 | $91,457 | +0.35% | |
| 2025-11-07 | Sale | LAMATTINA JOHN L | director | 2,034 0.0111% | $205.45 | $417,885 | -1.80% | |
| 2025-11-07 | Sale | Gray Nancy Ryan | director | 3,015 0.0165% | $205.45 | $619,432 | -1.80% | |
| 2025-11-03 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $191.05 | $89,219 | +3.97% | |
| 2025-10-01 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $179.44 | $83,800 | +9.65% | |
| 2025-09-23 | Sale | Aryeh Jason | director | 10,000 0.0511% | $170.81 | $1.71M | +14.87% | |
| 2025-09-02 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $162.26 | $75,775 | +18.41% | |
| 2025-08-01 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $131.88 | $61,586 | +43.79% |
| Davis Todd C | Chief Executive Officer | 161234 0.8086% | $37.38M | 4 | 7 | +21.25% |
| Aryeh Jason | director | 69289 0.3475% | $16.06M | 16 | 28 | +22.85% |
| KOZARICH JOHN W | director | 42253 0.2119% | $9.8M | 11 | 25 | +5.21% |
| Reardon Andrew | CLO & Secretary | 41382 0.2075% | $9.59M | 0 | 9 | |
| Sabba Stephen L | director | 32793 0.1644% | $7.6M | 3 | 8 | +53.3% |
| LAMATTINA JOHN L | director | 30724 0.1541% | $7.12M | 1 | 8 | +21.14% |
| Espinoza Octavio | Chief Financial Officer | 21010 0.1054% | $4.87M | 1 | 11 | |
| Gray Nancy Ryan | director | 8094 0.0406% | $1.88M | 0 | 2 | |
| Loeb Daniel S | 2027378 10.1668% | $469.99M | 2 | 1 | <0.0001% | |
| HIGGINS JOHN L | director | 422984 2.1212% | $98.06M | 7 | 25 | +13.79% |
| FOEHR MATTHEW W | President and COO | 173354 0.8693% | $40.19M | 7 | 13 | +42.46% |
| BVF PARTNERS L P/IL | 130175 0.6528% | $30.18M | 42 | 13 | +48.5% | |
| MEGLASSON MARTIN | V-P, Discovery Research | 102250 0.5128% | $23.7M | 4 | 1 | <0.0001% |
| MAIER PAUL V | Sr. V-P, CFO | 78251 0.3924% | $18.14M | 0 | 7 | |
| KNOTT DAVID M | director | 66152 0.3317% | $15.34M | 29 | 24 | +12.84% |
| Korenberg Matthew E | President & COO | 50777 0.2546% | $11.77M | 0 | 10 | |
| Dziewanowska Zofia E | VP, Clinical Research | 33977 0.1704% | $7.88M | 0 | 1 | |
| Berkman Charles S | SVP, Gen. Counsel & Secretary | 27763 0.1392% | $6.44M | 4 | 14 | +29.71% |
| Patel Sunil | director | 24524 0.123% | $5.69M | 4 | 2 | +36.17% |
| JOHNSON IRVING S | director | 22929 0.115% | $5.32M | 0 | 2 | |
| DeSilva Nishan M | VP, Finance & Strategy and CFO | 22282 0.1117% | $5.17M | 1 | 4 | +51.07% |
| Sharp John P | VP Finance and CFO | 17667 0.0886% | $4.1M | 0 | 5 | |
| Kazmi Syed | VP, Bus. Dev. & Strategic Plan | 14230 0.0714% | $3.3M | 0 | 2 | |
| ROCCA MICHAEL A | director | 8000 0.0401% | $1.85M | 0 | 1 | |
| NEGRO-VILAR ANDRES | Exe V-P, R & D, CSO | 7233 0.0363% | $1.68M | 0 | 3 | |
| CROSS ALEXANDER D | director | 6001 0.0301% | $1.39M | 0 | 3 | |
| GROVES ERIC S | V-P, Project Management | 5127 0.0257% | $1.19M | 0 | 1 | |
| Herman Melanie J | Director of Accounting | 3297 0.0165% | $764,310.54 | 2 | 6 | +28.79% |
| PETTTIT WILLIAM A | Sr. V-P, HR and Administration | 889 0.0045% | $206,087.98 | 0 | 3 | |
| ELAN CORP PLC | 10 percent owner | 0 0% | $0 | 0 | 2 | |
| BROADDUS WARNER R | V-P, Gen. Counsel & Secy. | 0 0% | $0 | 0 | 2 | |
| LITALIEN JAMES J | Sr. V-P, Reg Affairs & Comp. | 0 0% | $0 | 0 | 3 | |
| CROUCH TAYLOR | Sr. V-P, Ops & Pres. Int'l | 0 0% | $0 | 0 | 1 |
$159,914,414 | 243 | 18.52% | $4.91B | |
Ligand Pharmaceuticals Incorporated (LGND) | $66,736,176 | 136 | 27.54% | $4.62B |
$193,151,375 | 134 | 8.18% | $4.54B | |
$224,662,742 | 52 | 32.03% | $4.92B | |
$11,583,737 | 45 | 49.75% | $3.76B | |
$104,428,685 | 44 | 22.55% | $3.48B | |
$1,275,975,557 | 32 | 19.44% | $3.78B | |
$61,717,660 | 28 | 36.84% | $4.74B | |
$5,066,938 | 27 | 26.38% | $4.71B | |
$112,580,865 | 16 | 0.64% | $3.69B | |
$74,969,332 | 16 | 46.49% | $5.57B | |
$174,105,409 | 15 | 10.88% | $5.23B | |
$91,269,919 | 12 | 12.86% | $4.29B | |
$25,064,843 | 9 | 12.75% | $5.74B | |
$1,711,150 | 9 | 31.59% | $4.08B | |
$91,589,325 | 7 | -6.97% | $3.37B | |
$545,418 | 6 | 11.41% | $3.99B | |
$2,246,813 | 6 | 70.15% | $5.64B | |
$50,990,767 | 2 | 19.79% | $5.16B |
| Increased Positions | 182 | +51.85% | 2M | +9.98% |
| Decreased Positions | 148 | -42.17% | 2M | -9.76% |
| New Positions | 69 | New | 305,687 | New |
| Sold Out Positions | 30 | Sold Out | 871,531 | Sold Out |
| Total Postitions | 385 | +9.69% | 21M | +0.22% |
| Blackrock, Inc. | $548,377.00 | 14.42% | 2.88M | -29,214 | -1% | 2025-09-30 |
| Vanguard Group Inc | $394,722.00 | 10.38% | 2.08M | -13,088 | -0.63% | 2025-09-30 |
| Janus Henderson Group Plc | $198,166.00 | 5.21% | 1.04M | -18,356 | -1.73% | 2025-09-30 |
| Macquarie Group Ltd | $142,922.00 | 3.76% | 751,788 | -174,766 | -18.86% | 2025-09-30 |
| State Street Corp | $142,461.00 | 3.75% | 749,360 | -394 | -0.05% | 2025-09-30 |
| Congress Asset Management Co | $126,862.00 | 3.34% | 667,311 | +19,370 | +2.99% | 2025-09-30 |
| Chicago Capital, Llc | $108,099.00 | 2.84% | 568,611 | -3,214 | -0.56% | 2025-09-30 |
| Stephens Investment Management Group Llc | $105,424.00 | 2.77% | 554,542 | -50,271 | -8.31% | 2025-09-30 |
| Massachusetts Financial Services Co /Ma/ | $103,010.00 | 2.71% | 541,845 | +202,103 | +59.49% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $99,601.00 | 2.62% | 523,913 | -180,609 | -25.64% | 2025-09-30 |